The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical goods seems to be exempt, at least for now.

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of insolvency and Novartis hired a new top lawyer.

At the BioTrinity Conference, experts champion government funding programmes to bridge gap the in UK venture capital financing.

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma environment.

BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer disease.

T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity treatment.

Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene and cell therapies.

The sweeping workforce reduction that began Tuesday was made worse by mistakes and poor communication, including directions for some CMS employees to contact a director who died last year.

Teams working on device communications and policy were cut from the agency on Tuesday, according to multiple FDA workers.

Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of Tofidence.

Plans outlined by HHS Secretary Robert F Kennedy, Jr look set to target jobs at the US Department of Health & Human Services (HHS).

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Amneal Pharmaceuticals, along with Shilpa Medicare, has launched the new presentation of bortezomib, Boruzu.

Matthew Yelovich, partner at Cleary Gottlieb, discusses the appeals of Elizabeth Holmes and Ramesh “Sunny” Balwani and the Ninth Circuit’s recent affirmation of their convictions.

Charles River Laboratories will work directly with the platform.

Marcel Botha, CEO of 10XBeta, discusses lessons from The Spiro Wave project that can be applied in creating more agile and responsive systems for future public health emergencies.

The latest news for pharma industry insiders.

The platform can reportedly outperform traditional methods.

Apellis Pharmaceuticals has announced US FDA acceptance of the sNDA and the granting of priority review status to Empaveli

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.